Article Text
Abstract
Introduction/Background Objective: The objective of this study was to determine the cervical cancer burden in Turkey during a nation-based cervical cancer screening program.
Methodology Methods: The database of the Turkish Ministry of Health was searched in order to identify all consecutive cervical cancer patients during 1st Jan 2019 and 31th Dec 2019 for this retrospective, nationwide, cohort study. The incidence of cervical cancer and the 3-year overall survival of the patients were investigated.
Results Results: With an age-standardized incidence of 4.2/100.000, cervical cancer is the 10th most common cancer among women in Turkey. During the study period, 658.000 women were screened for cervical cancer and 2539 new cervical cases were detected nationwide. The median age of the patients was 53 (range, 20–94) years. Cervical biopsy revealed HSIL in 195 (7.7%) women before the final diagnosis and 1671 (65.8%) cases were associated with HPV 16/18. The histologic distribution of the cases were as follows: squamous cell carcinoma in 1972 (77.7%), adenocarcinoma in 380 (15.0%) and adenosquamous cell carcinoma in 54 (2.1%) women. Primary chemoradiation was applied as primary treatment in 1285 (50.6%) women whereas 1254 (49.4%) underwent surgery. There were 938 (74.8%) radical and 249 (19.8%) simple hysterectomies. With a median follow-up of 28 months, the 3-year overall survival rates were 92.7%, 89.8% and 83.6% for stage IB1, IB2 and IB3, respectively. The 3-year overall survival rate for stage IIB was 79.1%. According to histologic subtypes, the 3-year overall survival rates were 71.9%, 72.0%, and 70.9% for women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma, respectively.
Conclusion Conclusion: In spite of a 10-years’ experience of a nation-based cervical cancer screening program, cervical cancer still seems to represent an important tumor burden in Turkey.
Disclosures NONE